Printer Friendly

MICHAEL CHRISTIE, PH.D. JOINS ZYNAXIS AS VICE PRESIDENT OF PROCESS DEVELOPMENT

 MICHAEL CHRISTIE, PH.D. JOINS ZYNAXIS
 AS VICE PRESIDENT OF PROCESS DEVELOPMENT
 MALVERN, Pa., Oct. 20 /PRNewswire/ -- Zynaxis, Inc. (NASDAQ: ZNXS) today announced that Michael Christie, Ph.D. has joined the company as vice president of process development for the Therapeutic Division. Dr. Christie joins Zynaxis from SmithKline Beecham Chemicals where he was director of Chemical Development.
 Dr. Christie has over 14 years experience in process research and development for bulk pharmaceuticals. He was with SmithKline Beecham from 1981 to 1992 and was with Smith, Kline and French Laboratories for the three years prior to that. Michael Christie received his Ph.D. from Massachusetts Institute of Technology and has two awards to his credit; the Director's Impact Award from the Consumer Brands Division at SmithKline Beecham and the Award for Scientific Creativity from Smith, Kline and French.
 Thomas Cekoric Jr., president and CEO of Zynaxis stated: "The appointment of Dr. Christie is part of our growth strategy to develop clinical materials utilizing our proprietary drug delivery technology. We are very pleased to have Michael with us."
 Zynaxis, Inc. is a biotechnology company engaged in the development of new therapeutic drug delivery systems and advanced cellular diagnostic systems.
 -0- 10/20/92
 /CONTACT: Thomas Cekoric Jr., president and CEO of Zynaxis, Inc. 215-889-2200, or Susan Sherman of Cameron Associates, 212-644-9560, for Zynaxis, Inc./
 (ZNXS) CO: Zynaxis, Inc. ST: Pennsylvania IN: MTC SU: PER


TS-OS -- NY023 -- 2059 10/20/92 09:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 20, 1992
Words:241
Previous Article:PPG TO REDEEM 10-1/8 PERCENT NOTES DUE 1995
Next Article:SECOND QUARTER PROFITS MORE THAN DOUBLE AT AARON RENTS
Topics:


Related Articles
ZYNAXIS, INC. COMPLETES PUBLIC OFFERING OF 2.5 MILLION SHARES
OVER-ALLOTMENT OPTION EXERCISED IN ZYNAXIS PUBLIC OFFERING
WALTER BRANDES JOINS ZYNAXIS AS VICE PRESIDENT OF SALES AND MARKETING
DR. MARJORIE CHRISTIE APPOINTED DIRECTOR OF REGULATORY SCIENCES AT CYTOTHERAPEUTICS
ZYNAXIS AND SECRETECH ANNOUNCE MERGER PLANS; FOCUS ON DRUG DELIVERY STRENGTHENED
Creative BioMolecules, Inc. Announces New Senior Management Structure.
Maxygen Appoints George Poste to its Board of Directors and Announces Additions to Senior Management.
Executive changes. (Random Samples).
Charles Richardson Joins LigoCyte Pharmaceuticals as Senior Vice President, Research and Development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters